SCHEMBL3014630

SCHEMBL3014630

O=S(=O)(c1cc(C(F)(F)F)ccc1Cl)N1CCN(c2nc(-c3ccc(Cl)cc3Cl)cs2)CC1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.54
ALDH1A1 P00352 4/20 0.51
L3MBTL1 Q9Y468 4/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
TSHR P16473 2/20 0.51
ATM Q13315 1/20 0.51
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.44
LMNA P02545 3/20 0.44
MAPT P10636 1/20 0.44
EGFR P00533 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
HSD11B1 P28845 1/20 0.42
ALOX15 P16050 1/20 0.40
MAPK1 P28482 2/20 0.39
GPR6 P46095 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016116 0.90 AR (0.63) ARALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3013011 0.89 SMN1; SMN2 (0.54) ARALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3019325 0.88 AR (0.52) ARALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3010918 0.87 ALDH1A1 (0.53) ARALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3010933 0.86 AR (0.53) ARALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3020324 0.85 RAB9A (0.51) ARALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3016695 0.85 AR (0.54) ARALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3018011 0.85 AR (0.64) ARALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3011631 0.85 AR (0.54) ARALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3006723 0.85 LMNA (0.57) ARALDH1A1L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.